ANNE-MARIE OSIBAJO: Open Payments
NPI 1154859262 · SUMMIT, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$738 in 37 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $405 · 2025 $738
Food & beverage: $738
| Company | Payments | Amount |
|---|---|---|
| Eisai Inc. | 17 | $349 |
| ABBVIE INC. | 4 | $90 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $79 |
| Alkermes, Inc. | 3 | $66 |
| Lilly USA, LLC | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Neurocrine BioSciences, Inc. | 2 | $41 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
Products named: Leqembi, VRAYLAR, CAPLYTA, VIVITROL, KISUNLA, REXULTI, INGREZZA, COBENFY.
Industry payments across NJ — which companies pay providers there.
